RANY ABURASHED
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
- Where
- Dearborn, MI
- NPI
- 1790909711
- Received
- $450,238 in 458 records, 2019 to 2025 ($440,418 general, $9,819 research)
- As principal investigator
- $1,462,495 of research payments to others in 408 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 4 | $102 |
| 2024 | General payment | 3 | $753 |
| 2023 | General payment | 8 | $48,798 |
| 2022 | General payment | 21 | $24,238 |
| 2022 | Research payment | 4 | $5,041 |
| 2021 | General payment | 71 | $89,353 |
| 2021 | Research payment | 2 | $1,567 |
| 2020 | General payment | 89 | $70,330 |
| 2020 | Research payment | 3 | $677 |
| 2019 | General payment | 239 | $206,842 |
| 2019 | Research payment | 14 | $2,534 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 99 | $251,803 |
| Consulting Fee | 25 | $93,801 |
| Acquisitions | 1 | $48,167 |
| Travel and Lodging | 70 | $37,729 |
| Research payment | 23 | $9,819 |
| Food and Beverage | 238 | $8,784 |
| Education | 2 | $131 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-04-24 | Genentech USA, Inc. | $28 | Food and Beverage | In-kind items and services | Ocrevus Zunovo Biological, Immunology | 2025 | |
| 2025-04-14 | Biogen, Inc. | $28 | Food and Beverage | In-kind items and services | TYSABRI Biological, Neurology | 2025 | |
| 2025-01-30 | Celgene Corporation | $29 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2025-01-23 | Celgene Corporation | $16 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2025 | |
| 2024-11-13 | Intuitive Surgical, Inc. | $709 | Travel and Lodging | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-11-13 | Intuitive Surgical, Inc. | $19 | Travel and Lodging | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-06-03 | Genentech USA, Inc. | $24 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2024 | |
| 2023-11-26 | SCILEX PHARMACEUTICALS INC. | $20 | Food and Beverage | In-kind items and services | ZTLido Drug, Analgesic | 2023 | |
| 2023-11-20 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | Enspryng Biological, Immunology | 2023 | |
| 2023-07-18 | Alnylam Pharmaceuticals Inc. | $26 | Food and Beverage | In-kind items and services | AMVUTTRA Drug, Genetic Disease | 2023 | |
| 2023-06-13 | Genentech USA, Inc. | $22 | Food and Beverage | In-kind items and services | Ocrevus Biological, Immunology | 2023 | |
| 2023-05-08 | TG Therapeutics, Inc. | $104 | Food and Beverage | In-kind items and services | BRIUMVI Drug, Immunology | 2023 | |
| 2023-03-29 | Medtronic, Inc. | $48,167 | Acquisitions | Cash or cash equivalent | 2023 | ||
| 2023-03-20 | TG Therapeutics, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRIUMVI Drug, Immunology | 2023 | |
| 2023-01-30 | Nevro Corp. | $34 | Food and Beverage | In-kind items and services | Senza Device, Spinal Cord Stimulator | 2023 | |
| 2022-11-30 | Novartis Pharmaceuticals Corporation | $2,683 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-11-15 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | DUOPA Drug, NEUROSCIENCE | 2022 | |
| 2022-11-10 | GENZYME CORPORATION | $1,978 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-10-26 | Novartis Pharmaceuticals Corporation | $983 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-09-01 | GENZYME CORPORATION | $1,130 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-07-28 | GENZYME CORPORATION | $1,978 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-07-15 | HARMONY BIOSCIENCES LLC | $17 | Food and Beverage | Cash or cash equivalent | Wakix Drug, Neurological Disorders | 2022 | |
| 2022-07-01 | EMD Serono, Inc. | $3,080 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-06-14 | EMD Serono, Inc. | $3,080 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2022 | |
| 2022-06-14 | EMD Serono, Inc. | $3,080 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-06-10 | EMD Serono, Inc. | $275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2022 | |
| 2022-06-09 | EMD Serono, Inc. | $1,473 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-06-09 | EMD Serono, Inc. | $646 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-06-09 | EMD Serono, Inc. | $336 | Travel and Lodging | Cash or cash equivalent | 2022 | ||
| 2022-06-09 | EMD Serono, Inc. | $100 | Food and Beverage | Cash or cash equivalent | Mavenclad Drug, Neurology | 2022 | |
| 2022-05-18 | Novartis Pharmaceuticals Corporation | $392 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-05-13 | GENZYME CORPORATION | $2,628 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-05-12 | SANOFI-AVENTIS U.S. LLC | $125 | Food and Beverage | In-kind items and services | AUBAGIO Drug, Neurology | 2022 | |
| 2022-05-10 | TG Therapeutics, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-03-10 | Biogen, Inc. | $1,836 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, Neurology | 2022 | |
| 2022-03-10 | Genentech, Inc. | $1,200 | Consulting Fee | Cash or cash equivalent | Drug | 2022 | |
| 2022-02-24 | Novartis Pharmaceuticals Corporation | $983 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | 2022 |
| 2022-02-23 | EMD Serono, Inc. | $275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2022 | |
| 2022-01-19 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-01-06 | Biogen, Inc. | $565 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, Neurology | 2022 | |
| 2021-12-07 | Novartis Pharmaceuticals Corporation | $4 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-11-19 | EMD Serono, Inc. | $3,080 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2021 | |
| 2021-11-18 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-11-11 | SANOFI-AVENTIS U.S. LLC | $48 | Food and Beverage | In-kind items and services | AUBAGIO Drug, Neurology | 2021 | |
| 2021-11-10 | Biogen, Inc. | $30 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-11-09 | E.R. Squibb & Sons, L.L.C. | $4,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-11-09 | Novartis Pharmaceuticals Corporation | $317 | Research payment | In-kind items and services | ARZERRA Drug, HEMATOLOGY | PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH ARZERRA RESEARCH | 2021 |
| 2021-11-05 | GENZYME CORPORATION | $4,746 | Consulting Fee | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2021 | |
| 2021-11-02 | E.R. Squibb & Sons, L.L.C. | $4,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-11-01 | Biogen, Inc. | $1,695 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-10-29 | GENZYME CORPORATION | $2,184 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-10-28 | GENZYME CORPORATION | $1,911 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2021 | |
| 2021-10-25 | Biogen, Inc. | $4,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, NEUROLOGY | 2021 | |
| 2021-10-25 | Biogen, Inc. | $50 | Food and Beverage | Cash or cash equivalent | VUMERITY Drug, NEUROLOGY | 2021 | |
| 2021-10-22 | GENZYME CORPORATION | $4,095 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2021 | |
| 2021-10-22 | GENZYME CORPORATION | $16 | Food and Beverage | In-kind items and services | AUBAGIO Drug, Neurology | 2021 | |
| 2021-10-21 | E.R. Squibb & Sons, L.L.C. | $81 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-10-20 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-10-14 | E.R. Squibb & Sons, L.L.C. | $44 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-10-11 | Genentech USA, Inc. | $4,800 | Consulting Fee | Cash or cash equivalent | OCREVUS Biological, Immunology | 2021 | |
| 2021-10-08 | Genentech USA, Inc. | $4,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OCREVUS Biological, Immunology | 2021 | |
| 2021-10-08 | Genentech USA, Inc. | $2,530 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OCREVUS Biological, Immunology | 2021 | |
| 2021-10-08 | Genentech USA, Inc. | $39 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-10-08 | Genentech USA, Inc. | $22 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-10-08 | Novartis Pharmaceuticals Corporation | $11 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-10-07 | Genentech USA, Inc. | $4,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-10-07 | Genentech USA, Inc. | $1,921 | Travel and Lodging | Cash or cash equivalent | 2021 | ||
| 2021-10-07 | Genentech USA, Inc. | $864 | Travel and Lodging | Cash or cash equivalent | 2021 | ||
| 2021-10-07 | Genentech USA, Inc. | $110 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-10-06 | Novartis Pharmaceuticals Corporation | $1,064 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-09-30 | Janssen Pharmaceuticals, Inc | $45 | Food and Beverage | In-kind items and services | Ponvory Drug, Neuroscience | 2021 | |
| 2021-09-23 | Janssen Pharmaceuticals, Inc | $2,580 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-09-23 | Genentech USA, Inc. | $112 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-09-23 | Biogen, Inc. | $4 | Food and Beverage | In-kind items and services | VUMERITY Drug, NEUROLOGY | 2021 | |
| 2021-09-22 | Biogen, Inc. | $1,695 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-09-20 | Novartis Pharmaceuticals Corporation | $10 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-09-16 | Genentech USA, Inc. | $4,040 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OCREVUS Biological, Immunology | 2021 | |
| 2021-09-16 | Genentech USA, Inc. | $47 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-09-13 | Biogen, Inc. | $4,520 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VUMERITY Drug, NEUROLOGY | 2021 | |
| 2021-09-13 | Biogen, Inc. | $80 | Food and Beverage | Cash or cash equivalent | VUMERITY Drug, NEUROLOGY | 2021 | |
| 2021-09-02 | Genentech USA, Inc. | $2,530 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OCREVUS Biological, Immunology | 2021 | |
| 2021-09-02 | Genentech USA, Inc. | $21 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-08-20 | Genentech USA, Inc. | $1,010 | Consulting Fee | Cash or cash equivalent | OCREVUS Biological, Immunology | 2021 | |
| 2021-08-13 | EMD Serono, Inc. | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-08-10 | Genentech USA, Inc. | $22 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2021 | |
| 2021-08-05 | Celgene Corporation | $26 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-07-22 | Novartis Pharmaceuticals Corporation | $2,596 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-06-24 | GENZYME CORPORATION | $1,250 | Research payment | In-kind items and services | LEMTRADA Biological, Neurology | A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly S | 2021 |
| 2021-06-23 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-06-22 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-06-17 | Biogen, Inc. | $1,695 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-06-14 | EMD Serono, Inc. | $1,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2021 | ||
| 2021-06-14 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-05-30 | Novartis Pharmaceuticals Corporation | $5 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-05-11 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-05-10 | Biogen, Inc. | $8 | Food and Beverage | In-kind items and services | VUMERITY Drug, NEUROLOGY | 2021 | |
| 2021-04-27 | EMD Serono, Inc. | $275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2021 | |
| 2021-04-20 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-04-06 | Celgene Corporation | $1,550 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-04-01 | Biogen, Inc. | $3,013 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-03-28 | Celgene Corporation | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-03-23 | EMD Serono, Inc. | $1,540 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2021 | |
| 2021-03-22 | Novartis Pharmaceuticals Corporation | $16 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-03-22 | Biogen, Inc. | $9 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2021-03-16 | Novartis Pharmaceuticals Corporation | $1,064 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-03-15 | F. Hoffmann-La Roche AG | $6,000 | Consulting Fee | Cash or cash equivalent | Tamiflu Drug, Virology & Specialty Care | 2021 | |
| 2021-03-11 | Genentech USA, Inc. | $2,185 | Consulting Fee | Cash or cash equivalent | OCREVUS Biological, Immunology | 2021 | |
| 2021-03-08 | Novartis Pharmaceuticals Corporation | $9 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-03-02 | Novartis Pharmaceuticals Corporation | $10 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-02-22 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-02-11 | Novartis Pharmaceuticals Corporation | $6 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-02-04 | Novartis Pharmaceuticals Corporation | $15 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-01-28 | Biogen, Inc. | $4 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2021 | |
| 2020-12-17 | Celgene Corporation | $2,170 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-12-02 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-11-07 | Novartis Pharmaceuticals Corporation | $14 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-11-05 | Novartis Pharmaceuticals Corporation | $1,064 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-10-15 | Genentech USA, Inc. | $2,185 | Consulting Fee | Cash or cash equivalent | OCREVUS Biological, Immunology | 2020 | |
| 2020-10-08 | Biogen, Inc. | $2,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2020 | |
| 2020-09-25 | Novartis Pharmaceuticals Corporation | $9 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-09-24 | Novartis Pharmaceuticals Corporation | $8 | Food and Beverage | In-kind items and services | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-08-27 | Novartis Pharmaceuticals Corporation | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KESIMPTA Drug, NEUROSCIENCE | 2020 | |
| 2020-08-24 | Teva Pharmaceuticals USA, Inc. | $15 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2020 | |
| 2020-08-11 | E.R. Squibb & Sons, L.L.C. | $13 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-08-03 | GENZYME CORPORATION | $574 | Research payment | In-kind items and services | LEMTRADA Biological, Neurology | A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS034 | 2020 |
| 2020-07-31 | GENZYME CORPORATION | $1,298 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2020 | |
| 2020-07-17 | GENZYME CORPORATION | $1,038 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2020 | |
| 2020-07-17 | GENZYME CORPORATION | $1,038 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2020 | |
| 2020-07-16 | Celgene Corporation | $2,170 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-07-16 | GENZYME CORPORATION | $1,038 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2020 | |
| 2020-07-13 | SANOFI-AVENTIS U.S. LLC | $21 | Food and Beverage | In-kind items and services | AUBAGIO Drug, Neurology | 2020 | |
| 2020-07-07 | Genentech USA, Inc. | $14 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2020 | |
| 2020-06-30 | Celgene Corporation | $1,440 | Consulting Fee | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-06-27 | Genentech USA, Inc. | $4,120 | Consulting Fee | Cash or cash equivalent | OCREVUS Biological, Immunology | 2020 | |
| 2020-06-19 | GENZYME CORPORATION | $4,585 | Consulting Fee | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2020 | |
| 2020-06-18 | Celgene Corporation | $2,170 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-06-15 | E.R. Squibb & Sons, L.L.C. | $28 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-06-05 | Novartis Pharmaceuticals Corporation | $2,128 | Consulting Fee | Cash or cash equivalent | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-05-26 | EMD Serono, Inc. | $24 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-05-16 | Genentech USA, Inc. | $2,439 | Consulting Fee | Cash or cash equivalent | OCREVUS Biological, Immunology | 2020 | |
| 2020-05-05 | Celgene Corporation | $620 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-04-16 | Mallinckrodt Hospital Products Inc. | $3,575 | Consulting Fee | Cash or cash equivalent | ACTHAR Biological, IMMUNOLOGY | 2020 | |
| 2020-03-31 | GENZYME CORPORATION | $74 | Research payment | In-kind items and services | LEMTRADA Biological, Neurology | A long-term follow-up study for Multiple Sclerosis patients who have completed the alemtuzumab extension study (CAMMS034 | 2020 |
| 2020-03-31 | GENZYME CORPORATION | $28 | Research payment | In-kind items and services | LEMTRADA Biological, Neurology | An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-sponsored Studies of Alemtuzumab | 2020 |
| 2020-03-25 | Genentech USA, Inc. | $506 | Travel and Lodging | Cash or cash equivalent | OCREVUS Biological, Immunology | 2020 | |
| 2020-03-12 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | AIMOVIG Biological, NEUROSCIENCE | 2020 | |
| 2020-03-10 | KYOWA KIRIN, INC. | $17 | Food and Beverage | In-kind items and services | NOURIANZ Drug, ADENOSINE A2A RECEPTORS | 2020 | |
| 2020-03-08 | Allergan, Inc. | $13 | Food and Beverage | In-kind items and services | BOTOX Biological, HYPERHYDROSIS | 2020 | |
| 2020-03-04 | Novartis Pharmaceuticals Corporation | $7 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-03-02 | Novartis Pharmaceuticals Corporation | $13 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-02-28 | EMD Serono, Inc. | $3,960 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Mavenclad Drug, Neurology | 2020 | |
| 2020-02-27 | Allergan, Inc. | $16 | Food and Beverage | In-kind items and services | BOTOX Biological, HYPERHYDROSIS | 2020 | |
| 2020-02-25 | Genentech USA, Inc. | $19 | Food and Beverage | In-kind items and services | OCREVUS Biological, Immunology | 2020 | |
| 2020-02-24 | Novartis Pharmaceuticals Corporation | $10 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-02-22 | Celgene Corporation | $4,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-02-22 | Celgene Corporation | $541 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-02-22 | Celgene Corporation | $520 | Travel and Lodging | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-02-22 | Celgene Corporation | $60 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-02-22 | Celgene Corporation | $60 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-02-22 | Celgene Corporation | $50 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-02-22 | Celgene Corporation | $29 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-02-22 | Celgene Corporation | $8 | Food and Beverage | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2020 | |
| 2020-02-20 | GENZYME CORPORATION | $2,465 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LEMTRADA Biological, Neurology | 2020 | |
| 2020-02-20 | GENZYME CORPORATION | $124 | Food and Beverage | In-kind items and services | LEMTRADA Biological, Neurology | 2020 | |
| 2020-02-20 | Bard Peripheral Vascular, Inc. | $99 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-02-20 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | LEMTRADA Biological, Neurology | 2020 | |
| 2020-02-17 | GENZYME CORPORATION | $17 | Food and Beverage | In-kind items and services | LEMTRADA Biological, Neurology | 2020 | |
| 2020-02-13 | Allergan, Inc. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2020 | |
| 2020-02-08 | GENZYME CORPORATION | $9,968 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUBAGIO Drug, Neurology | 2020 | |
| 2020-02-08 | GENZYME CORPORATION | $330 | Travel and Lodging | In-kind items and services | AUBAGIO Drug, Neurology | 2020 | |
| 2020-02-08 | GENZYME CORPORATION | $214 | Travel and Lodging | In-kind items and services | AUBAGIO Drug, Neurology | 2020 | |
| 2020-02-08 | GENZYME CORPORATION | $99 | Travel and Lodging | In-kind items and services | AUBAGIO Drug, Neurology | 2020 | |
| 2020-02-08 | GENZYME CORPORATION | $60 | Food and Beverage | In-kind items and services | AUBAGIO Drug, Neurology | 2020 | |
| 2020-02-08 | GENZYME CORPORATION | $51 | Food and Beverage | In-kind items and services | AUBAGIO Drug, Neurology | 2020 | |
| 2020-02-06 | Teva Pharmaceuticals USA, Inc. | $15 | Food and Beverage | In-kind items and services | AJOVY Biological, Central Nervous System | 2020 | |
| 2020-02-03 | Biogen, Inc. | $23 | Food and Beverage | In-kind items and services | AVONEX Biological, NEUROLOGY | 2020 | |
| 2020-01-30 | Novartis Pharmaceuticals Corporation | $22 | Food and Beverage | In-kind items and services | AIMOVIG Biological, NEUROSCIENCE | 2020 | |
| 2020-01-28 | Eisai Inc. | $13 | Food and Beverage | Cash or cash equivalent | Fycompa Drug, Neurology | 2020 | |
| 2020-01-25 | EMD Serono, Inc. | $743 | Travel and Lodging | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-25 | EMD Serono, Inc. | $52 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-25 | EMD Serono, Inc. | $31 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-25 | EMD Serono, Inc. | $23 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-25 | EMD Serono, Inc. | $15 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-25 | EMD Serono, Inc. | $12 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-25 | EMD Serono, Inc. | $12 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-25 | EMD Serono, Inc. | $3 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-24 | EMD Serono, Inc. | $292 | Travel and Lodging | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-24 | EMD Serono, Inc. | $82 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-24 | EMD Serono, Inc. | $7 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-24 | EMD Serono, Inc. | $2 | Food and Beverage | In-kind items and services | Mavenclad Drug, Neurology | 2020 | |
| 2020-01-23 | CATALYST PHARMACEUTICALS, INC. | $23 | Food and Beverage | In-kind items and services | FIRDAPSE Drug, NEUROLOGY | 2020 | |
| 2020-01-18 | GENZYME CORPORATION | $20 | Food and Beverage | In-kind items and services | 2020 | ||
| 2020-01-16 | Neurocrine BioSciences, Inc. | $16 | Food and Beverage | In-kind items and services | INGREZZA Drug, NEUROLOGY | 2020 | |
| 2020-01-14 | Novartis Pharmaceuticals Corporation | $12 | Food and Beverage | In-kind items and services | MAYZENT Drug, NEUROSCIENCE | 2020 | |
| 2020-01-13 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | DUOPA Drug, NEUROSCIENCE | 2020 | |
| 2020-01-11 | Biogen, Inc. | $7,088 | Consulting Fee | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2020 | |
| 2020-01-11 | Biogen, Inc. | $432 | Travel and Lodging | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2020 | |
| 2020-01-11 | Biogen, Inc. | $196 | Travel and Lodging | Cash or cash equivalent | TYSABRI Biological, NEUROLOGY | 2020 | |
| 2020-01-11 | Biogen, Inc. | $117 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2020 | |
| 2020-01-11 | Biogen, Inc. | $89 | Food and Beverage | In-kind items and services | TYSABRI Biological, NEUROLOGY | 2020 |
The latest 200 records of 458.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-22 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $8,743 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-12-17 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $2,122 | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 |
| 2025-11-24 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $83 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-10-14 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $498 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-10-14 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $55 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-10-06 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $8,577 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-09-19 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $1,286 | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 |
| 2025-09-15 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $83 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-09-15 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $118 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $6 | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 |
| 2025-07-02 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $332 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-07-02 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $1,697 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-05-27 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $5 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-05-27 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $249 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-05-16 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $1,908 | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 |
| 2025-04-28 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $1,876 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-04-07 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $1,000 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-04-07 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $1,378 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-04-07 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $100 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-04-07 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $1,100 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-02-19 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $1,908 | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 |
| 2025-02-18 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $415 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-02-18 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $799 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-01-06 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $1,707 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2025 |
| 2025-01-06 | GENZYME CORPORATION | MEMORIAL HEALTHCARE | $606 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2025 |
| 2024-12-03 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $29,743 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-12-03 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,863 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-11-18 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $2,122 | 70033093STR3001 | 2024 |
| 2024-10-21 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,863 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-10-21 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $8,811 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-10-15 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $407 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-10-02 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,606 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-10-02 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $249 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-09-13 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $830 | 70033093STR3001 | 2024 |
| 2024-09-04 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,000 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-08-23 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $2,729 | 70033093STR3001 | 2024 |
| 2024-07-29 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $3,138 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-07-24 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $415 | 70033093STR3001 | 2024 |
| 2024-07-22 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $125 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-07-22 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $415 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-06-19 | Janssen Research & Development, LLC | Biomdcl Rsrch Allnce Of New York Llc | $3,933 | 70033093STR3001 | 2024 |
| 2024-06-10 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $230 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-05-28 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $415 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-05-22 | Janssen Research & Development, LLC | Biomdcl Rsrch Allnce Of New York Llc | $1,349 | 70033093STR3001 | 2024 |
| 2024-04-22 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $166 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-04-15 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $50 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-04-08 | Janssen Research & Development, LLC | Biomdcl Rsrch Allnce Of New York Llc | $4,249 | 70033093STR3001 | 2024 |
| 2024-03-18 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,415 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-03-04 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $249 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-02-21 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $2,817 | 70033093STR3001 | 2024 |
| 2024-02-20 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $50 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-02-12 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,863 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-02-05 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $168 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-02-05 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,863 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-01-31 | Novartis Pharmaceuticals Corporation | INSIGHT HOSPITAL AND MEDICAL CENTER | $1,263 | A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus | 2024 |
| 2024-01-22 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $249 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-01-16 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $83 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-01-16 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $75 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2024-01-03 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $83 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2024 |
| 2024-01-03 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,863 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2024 |
| 2023-12-13 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $1,433 | 70033093STR3001 | 2023 |
| 2023-12-04 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $9,014 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-11-22 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $5,193 | 70033093STR3001 | 2023 |
| 2023-11-20 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $143 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-11-14 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $500 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2023 |
| 2023-11-14 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $415 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2023 |
| 2023-11-14 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $83 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-11-14 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $8,811 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-11-06 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $293 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-10-30 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $11,124 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-10-30 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,500 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-10-16 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $348 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-10-10 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $205 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-10-10 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $83 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-09-20 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $1,433 | 70033093STR3001 | 2023 |
| 2023-09-18 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $75 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-09-11 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $166 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-09-05 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,863 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-08-28 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,650 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-08-28 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,500 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-08-23 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $5,521 | 70033093STR3001 | 2023 |
| 2023-08-21 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $249 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-08-07 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $249 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-08-02 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $3,726 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-08-02 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,863 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-07-17 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,494 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-07-17 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $286 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-07-17 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $83 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-07-10 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,100 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-07-10 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $308 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-07-10 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $83 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-07-05 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $143 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-07-05 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $332 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-07-05 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $1,100 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-05-25 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $5,977 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-05-25 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $581 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Prima | 2023 |
| 2023-05-24 | Janssen Research & Development, LLC | Insight Rsrch Inst Inc. | $5,158 | 70033093STR3001 | 2023 |
| 2023-05-15 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $830 | A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Particip | 2023 |
| 2023-05-15 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $249 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2023 |
| 2023-05-15 | GENZYME CORPORATION | Memorial Hospital Memorial Healthcare Memorial Medica Associates | $3,397 | A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonre | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Dearborn, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Dearborn, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 107,423 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 109,976 | 1,793,561 | 10,077,331 |
| Median age B01002 | 33.3 | 37.9 | 40.2 |
| Under 18 B01001 | 28.7% | 23.6% | 21.2% |
| 65 and over B01001 | 13.7% | 16.6% | 18.6% |
| Households B11001 | 36,695 | 700,591 | 4,076,369 |
| Foreign born B05002 | 30.3% | 10.3% | 7.2% |
| Median household income B19013 | $65,324 | $60,539 | $72,875 |
| Median family income B19113 | $74,152 | $79,522 | $93,357 |
| Per capita income B19301 | $30,588 | $34,906 | $40,735 |
| Poverty rate B17001 | 24.3% | 20.8% | 13.2% |
| Unemployment rate B23025 | 6.6% | 8.7% | 5.7% |
| Civilian labor force B23025 | 45,028 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 21.7 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 34.6% | 27.6% | 32.4% |
| Housing units B25001 | 39,394 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 68.4% | 64.8% | 73.2% |
| Renters B25003 | 31.6% | 35.2% | 26.8% |
| Median home value B25077 | $218,800 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,327 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 87.3% | 47.9% | 72.4% |
| Black B03002 | 3.6% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 2.7% | 6.9% | 5.9% |
| Asian B03002 | 1.8% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Dearborn, MI.
Comments